Daiichi Sankyo Co Ltd - Company Profile
Powered by 
All the data and insights you need on Daiichi Sankyo Co Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Daiichi Sankyo Co Ltd Strategy Report
- Understand Daiichi Sankyo Co Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Daiichi Sankyo Co Ltd (Daiichi Sankyo) is a holding company, which carries out the research, development, manufacture, and marketing of pharmaceutical products. The company offers a wide range of prescription drugs, over the counter (OTC) drugs, vaccines, and others. Its portfolio encompasses medicines for cardiovascular, neurological, nephrological, diabetic, metabolic, and infectious diseases, and various types of cancers. Besides cancer, the company’s other research areas include rare diseases and immune disorders. Daiichi Sankyo sells its products through its group companies and an extensive network of medical representatives. It has operations in North America, South and Central America, Europe, and Asia. Daiichi Sankyo is headquartered in Tokyo, Japan.
Headquarters
Japan
Address
Daiichi Sankyo Bldg. A/B Kan, 3-5-1, Nihombashi Hon-Cho, Chuo-Ku, Tokyo, 103-8426
Website
www.daiichisankyo.co.jp
Telephone
81 3 62251111
No of Employees
17,435
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
4568 (TYO)
Revenue (2022)
$9.4B
22.4%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
63%
(2022 vs 2021)
Market Cap*
$58.9B
Net Profit Margin (2022)
XYZ
33.2%
(2022 vs 2021)
* As of and is in US$
Daiichi Sankyo Co Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Oncology: | Olmetec |
| Trastuzumab Deruxtecan | Benicar |
| Pexidartinib | Benicar HCT |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Regulatory Approval | In April, the company and AstraZeneca secured approval from the US Food and Drug Administration for datopotamab deruxtecan (Dato-DXd), a new treatment for a subset of breast cancer patients. |
| 2024 | Plans/Strategy | In March, the company and Mitsubishi Tanabe Pharma announced plans to end their marketing alliance agreement for certain drugs, Tenelia Tablets and Tenelia OD Tablets. |
| 2023 | Contracts/Agreements | In December, the company and Depixus entered into a partnership to utilize MAGNA technology to accelerate the RNA-targeted drug discovery program. |
Competitor Comparison
| Key Parameters | Daiichi Sankyo Co Ltd | Merck & Co Inc | Takeda Pharmaceutical Co Ltd | Astellas Pharma Inc | Chugai Pharmaceutical Co Ltd |
|---|---|---|---|---|---|
| Headquarters | Japan | United States of America | Japan | Japan | Japan |
| City | Chuo-Ku | Kenilworth | Chuo-Ku | Chuo-Ku | Chuo-Ku |
| State/Province | Tokyo | New Jersey | Tokyo | Tokyo | Tokyo |
| No. of Employees | 17,435 | 72,000 | 49,095 | 14,484 | 7,771 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Sunao Manabe | Chief Executive Officer; Chairman | Executive Board | 2023 | - |
| Hiroyuki Okuzawa | Chief Operating Officer; Director; President | Executive Board | 2023 | - |
| Takashi Fukuoka | Senior Executive Officer; Director; Head- Global Corporate Strategy; Chief Strategy Officer | Executive Board | 2023 | - |
| Shoji Hirashima | Senior Executive Officer; Head - Japan Business Unit; Director | Executive Board | 2022 | - |
| Masahiko Ohtsuki | Chief Digital Transformation Officer; Director; Head- Global DX; Senior Executive Officer | Executive Board | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward